Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Kaplan-Meier estimate
antibodies
antineoplastic agents
head and neck squamous cell carcinoma
immunological
patient outcomes
real-world observational study
treatment patterns
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
06
2023
accepted:
30
06
2023
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
[This corrects the article DOI: 10.3389/fonc.2023.1160144.].
Identifiants
pubmed: 37529689
doi: 10.3389/fonc.2023.1240947
pmc: PMC10390299
doi:
Types de publication
Published Erratum
Langues
eng
Pagination
1240947Commentaires et corrections
Type : ErratumFor
Informations de copyright
Copyright © 2023 Black, Hanna, Wang, Ramakrishnan, Goto, Turzhitsky and Hair.